Differences in biomarkers of cartilage matrix turnover and their changes over 2 years in adolescent and adult volleyball athletes

Heide Boeth*, Aoife MacMahon, A. Robin Poole, Frank Buttgereit, Patrik Önnerfjord, Pilar Lorenzo, Cecilia Klint, Anna Pramhed and Georg N. Duda

Abstract

Background: This study aimed at assessing the feasibility to assess longitudinal changes in biomarkers of cartilage turnover and to determine their relationship with patient-rated outcomes over 2 years in volleyball athletes.

Methods: Thirty-seven athletes were studied: 18 adolescents (age 15.9 ± 0.64 years) in a 2-year intensive volleyball training program and 19 adult recreational volleyball players (age 46.5 ± 4.9 years). Blood and serum samples were taken at baseline (BL) and 2-year follow-up (FU). Subjects completed the International Knee Documentation Committee (IKDC) Subjective Knee Form and the Short-Form 36 (SF-36) at BL.

Results: Thirteen adolescents (72%) had open growth plates at BL (BL open adolescents), the rest had closed growth plates at BL (BL closed adolescents), and all but one adolescent had closed growth plates at FU as assessed by MRI. BL open and closed adolescents had greater levels of the cartilage degradation-based biomarkers 45 mer collagenase peptide of type II collagen (C2C-HUSA) and C-telopeptide of type II collagen (CTX-II) than adults. BL open adolescents showed decreases in C2C-HUSA, collagen synthesis marker C-propeptide of type II procollagen (CPII), and CTXII, and adults showed increases in cartilage intermediate layer protein 2 (CILP-2) and C2C-HUSA. In adolescents, IKDC scores were correlated with CPII changes. In adults, SF-36 Physical Component Scores were correlated with cartilage oligomeric matrix protein (COMP) changes.

Conclusion: Significant differences in biomarker levels over time show the feasibility to assess their changes. Greater levels of C2C-HUSA and CTX-II in adolescents than in adults may reflect increased cartilage turnover in response to higher joint loading. CPII and COMP may be more reflective of subjective patient outcomes. These biomarkers may thus be useful in assessing mechanical loading-induced cartilage changes, their associated symptoms, and Osteoarthritis risk in athletes.

Keywords: Cartilage, Biomarkers, Volleyball, Athletes, Patient-rated outcomes, Osteoarthritis

* Correspondence: heide.boeth@charite.de
Julius Wolff Institute, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background

Osteoarthritis (OA) is the most common type of arthritis and causes more functional disability than any other disease (Felson 2014). Primary knee OA is frequently associated with mechanical overloading of joints (Kujala et al. 1994) and is characterized by degradation of the whole joint including cartilage, subchondral bone and surrounding soft tissue (Felson et al. 2000). Previous findings have suggested that high-impact physical activity (Kujala et al. 1994, Kujala et al. 1995, Buckwalter and Lane 1997, Amoako and Pujalte 2014) and/or prior knee injury (Muthuri et al. 2011, Richmond et al. 2013) increase the risk of developing primary OA. However, it is unclear how frequency and intensity of exercise affect human articular cartilage degradation (Hallett and Andrish 1994, Saxon et al. 1999).

Biomarkers of cartilage turnover may reflect structural cartilage changes and thus may identify patients at risk of early onset of OA (Rousseau and Delmas 2007). Previous studies have found that biomarkers of cartilage turnover are altered in athletes after a session of running (Kersting et al. 2005, Niehoff et al. 2011), as well as in varsity collegiate soccer, crew, and swimming athletes after a sports season (O’Kane et al. 2006, Hoch et al. 2012, Mateer et al. 2015). Although past studies have investigated longitudinal changes in biomarkers of cartilage turnover in athletes of a high-impact sport, e.g. soccer, over a sports season (O’Kane et al. 2006, Hoch et al. 2012, Mateer et al. 2015), more long-term changes in such biomarkers in an athletic population remain unclear. Some of these biomarkers may also remain elevated from 1 to 7 years post-injury in athletes who have suffered a knee injury (Ahlen et al. 2015, Kumahashi et al. 2015, Struglics et al. 2015). Additionally, it is important to understand how subjective clinical outcomes are related to changes in biomarkers of cartilage turnover in athletes, which may help determine which biomarkers are most reflective of such patients’ self-reported status.

Long-term changes in biomarkers of cartilage turnover in athletes of a high-impact sport are currently unknown. Moreover, the effects of exercise on cartilage wear in adolescent and adult athletes may be different due to the different developmental stages of these populations. It was previously found that femoral-tibial cartilage thickness increases in adolescent volleyball players and decreases in adult volleyball players over 2 years (Eckstein et al. 2014). Another study found that 64% of adolescent soccer players display knee abnormalities by Magnetic Resonance Imaging (MRI), particularly bone marrow edema (Soder et al. 2011). Thus, investigating differences between biomarkers of cartilage turnover in adolescent and adult athletes could provide insights into how these biomarkers reflect different cartilage changes and adaptations to exercise in these two populations.

The primary goals of this study were to compare values of and changes in biomarkers of cartilage turnover over 2 years between adolescent and adult volleyball players in order to investigate the roles of growth plate development and volleyball activity on biomarkers of cartilage turnover. The secondary goals were to assess the correlations between baseline (BL) patient-rated outcome measures (PROMs) and longitudinal changes in these biomarkers. Through these goals, we aimed to investigate the roles of volleyball activity and growth plate development on biomarkers of cartilage turnover, which could reflect both exercise-induced and pre-osteoarthritic knee degradation, and also to assess which biomarkers might be clinically relevant. Our hypotheses were that 1) adult volleyball athletes would have higher levels and increases in biomarkers of cartilage degradation than adolescent volleyball athletes, due to the former’s more advanced age and greater lifetime cumulative joint loading; 2) adolescent volleyball athletes would have higher levels and increases in biomarkers of cartilage synthesis due to their continuing growth; and 3) biomarkers of cartilage degradation would be associated with PROMs.

Methods

Subjects

This was a prospective, longitudinal cohort study (Level III) which received approval from an Institutional Review Board. A convenience sample of 40 volleyball athletes (20 adolescents and 20 adults) was initially recruited, and all provided written informed consent for participation. For adolescents, inclusion criteria were age less than or equal to 17 years, current participation in the 2-year volleyball training program at Olympiastützpunkt Berlin, and prior volleyball participation in a club for at least 3 years. For adults, inclusion criteria were age greater than 40 years (in order to have an adult cohort that was significantly older than the adolescent cohort and thus would have likely experienced greater joint degradation over time), past participation in the volleyball training program at Olympiastützpunkt Berlin, but with ongoing exclusive and continued volleyball participation for at least 2 h a day, twice a week. Exclusion criteria for both groups were prior knee injury requiring surgery less than 1 year prior to the BL evaluation. The volleyball training program at Olympiastützpunkt Berlin consisted of 2-h training sessions twice daily, 6 days a week, for 2 years.

Two adolescent males with Osgood-Schlatter disease were excluded due to its confounding effects on biomarkers of cartilage turnover and skeletal metabolism (Frantz et al. 2010). One adult male was excluded due to
insufficient serum and urine sample volumes. Thus, the final cohort consisted of 37 volleyball athletes, with 18 adolescents and 19 adults (Table 1). Biomarkers of cartilage turnover were evaluated in all subjects at BL and at 2-year follow-up (FU).

At BL, all subjects were evaluated by a self-reported questionnaire for knee pathology and prior knee injuries that required surgical intervention. One female adolescent had an ACL tear that had been surgically repaired. Two adolescent males and two adolescent females had patellar pain syndrome. Eight adults had prior knee surgery. Among the adult males, one had a lateral meniscectomy, one had lateral and medial meniscectomies and articular cartilage debridement, one had other knee surgery, and one had cartilage debridement and a meniscus surgery. Among the adult females, one had a nerve transaction and knee cartilage debridement, one had knee arthroscopy, one had meniscus surgery, and one had a medial meniscectomy. One male adult reported pain below the patella, and two adult females had knee pain. No subjects experienced injuries between BL and 2-year FU. Biomarker levels and patient-rated outcomes were compared between adults with and without prior knee injury to determine how this variable influenced results.

Sample collection
All blood samples were obtained following an overnight fast and urine samples were collected on the second morning void. Serum and urine samples were collected at both BL and at FU after subjects had received MRI scans and thus had been inactive and lying down for 45 min before being seated for approximately 10 min. Serum samples were obtained from 29 subjects at BL (11 adolescents and 18 adults) and 36 subjects at FU (17 adolescents and 19 adults). Serum samples were insufficient due to a limited amount of blood that had been taken in seven adolescent females and one adult female at BL and in one adolescent male at FU. One adolescent male was missing a urine sample at FU. However, these subjects were included in the analysis as they had adequate samples for at least one time point.

| Table 1 Subject Demographics |
|-----------------------------|
|                             |
| **Adolescents**             |
| Age [years] a               |
| 15.9 ± 0.64                 |
| Weight [kg] a               |
| 76 ± 10.3                   |
| Height [cm] a               |
| 188.3 ± 7.8                 |
| BMI [kg/m²] a              |
| 21.4 ± 1.8                  |
| Females b                   |
| 10 (56)                     |
| Prior knee injury b         |
| 1 (5)                       |
| **Adults**                  |
| Age [years] a               |
| 46.5 ± 4.9                  |
| Weight [kg] a               |
| 82.3 ± 16.2                 |
| Height [cm] a               |
| 183.2 ± 8.9                 |
| BMI [kg/m²] a              |
| 243 ± 2.9                   |
| Females b                   |
| 10 (52)                     |
| Prior knee injury b         |
| 8 (42)                      |

P-value
- Adolescent vs Adult
  - Age [years] a: 0.047*
  - Weight [kg] a: 0.081
  - Height [cm] a: 0.001*
  - BMI [kg/m²] a: >0.999
  - Females b: 0.0188*

* Statistically significant difference (P < 0.05)
* Values expressed as mean ± standard deviation
* Values expressed as N (% of age group)

Patient-rated outcomes
To assess subjective clinical status, all subjects completed the International Knee Documentation Committee (IKDC) Subjective Knee Form and the Short-Form 36 (SF-36) at BL. The IKDC is a validated patient-rated outcome measure that evaluates symptoms, function, and sports activity in patients with various knee problems (Irrgang et al. 2001). The SF-36 is a validated metric for general health outcomes (Patel et al. 2007), and both the Physical Component Score (PCS) and Mental Component Score (MCS) were assessed. For each outcomes measure, scores range from 0 to 100, with a lower score indicating greater disability.

Magnetic resonance imaging (MRI)
Since the adolescents’ growth status likely affected the levels of biomarkers assessed, the status of their femoral and tibial growth plates was assessed at BL and FU with magnetic resonance imaging (MRI). MRI was performed in a 1.5 T Avanto scanner (Siemens Medical Systems, Erlangen, Germany) using a dedicated 8-channel knee coil. The take-off leg was imaged in all participants in supine position with the leg in full extension. A 2D coronal proton-density (PD) weighted turbo spin-echo MR sequence with fat suppression (0.4167×0.4167 mm in-plane resolution, 3 mm slice thickness, 3.6 mm slice spacing, 29 ms echo time, 3520 ms repetition time, 150° flip angle) as well as a 3D axial T2-weighted Multi-Echo Data Image Combination (MEDIC) sequence (0.167×0.167 mm in-plane resolution, 1.2 mm slice thickness, 21 ms echo time, 38 ms repetition time, 8° flip angle) were used for imaging at both BL and FU. All images were assessed on a picture archiving communications system (PACS) by a radiologist with 12 years of experience in musculoskeletal imaging. The radiologist was blinded to the clinical information of each subject and to the time point of the MRI.

Biomarker analyses
Serum and urine samples were immediately stored at −70 °C until testing. After being frozen on dry ice, they were transported for assay to AnaMar AB (Lund, Sweden) and IBEX Pharmaceuticals (Montreal, Quebec, Canada).

The serum cartilage molecular biomarkers studied were the collagen degradation markers cartilage oligomeric matrix protein (COMP), cartilage intermediate layer protein 2 (CILP-2), and serum type II collagen cleavage neoepitope (sC2C), as well as the collagen synthesis marker C-propeptide of type II procollagen (CPII). COMP is expressed as U/L, and CILP-2, sC2C, and CPII are expressed as ng/mL.
The urine cartilage molecular biomarkers studied were the collagen degradation markers 45-mer collagenase-generated peptide of human type II collagen (C2C-HUSA) and CTX-II, which are expressed as ng/mmol of creatinine. At IBEX, all the samples were tested in duplicate for all assays (C2C, CPII, C2C-HUSA and CTX-II and urine creatinine). At AnaMar AB, all the samples were tested in duplicate for COMP and CILP-2. All study subjects were randomly assigned to the assay plates regardless of which group they belonged to. Both time points for each subject were always assayed on the same plate.

**Serum collagen degradation biomarkers**

COMP was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) (AnaMar AB) and the cartilage collagen degradation biomarker C2C (collagenase generated carboxy-terminal neopeptipe of type II collagen) using a competitive inhibition ELISA (IBEX). CILP-2 was assayed using an in-house research competitive ELISA (AnaMar AB).

**Serum collagen synthesis biomarkers**

CPII (type II procollagen carboxy-propeptide) was assayed using a competitive inhibition ELISA (IBEX).

**Urine type II collagen degradation biomarkers**

Two biomarkers of degradation were measured in urine samples: CTX-II (C-telopeptide of type II collagen) using a competitive assay (CartiLaps; IDS) and C2C-HUSA (collagenase-generated peptides of human type II collagen) using a sandwich assay (IBEX) (Cibere et al. 2009). Creatinine was measured at IBEX using an enzymatic colorimetric kit (QuantiChrom™; BioAssay Systems, Hayward, CA, USA).

**Biomarker assays**

The assay details, reproducibility (intra and inter assay variation) and accuracy of all these assays (recovery of added analyte) are described in detail on the websites of the manufacturers (interassay variability: 2–3%, intraassay variability: 2–4%, recovery: 93–116%) with the exception of the competitive CILP-2 assay which is as follows: Microtitre plates (Costar high binding 9018) were coated with a 61 amino acid long synthetic polypeptide from the CILP2 domain 1 (V551-D611 (UniProt Q8IUL8) Schafer-N, Copenhagen, Denmark). Plates were incubated at room temperature overnight. Plates were washed with PBS-Tween (PBS-T, Medicago) four times and incubated with block solution (1% Probumin from Millipore in PBS-T) for 2–3 h. Standard (range 100 ng/ml-0.14 ng/ml) and athlete serum samples were diluted 1:10 in conjugate buffer (Medicago 25-0142+ 0.1 mg/ml goat IgG from Sigma) and pre-incubated with HRP-coupled anti-CILP-2 antibody (polyclonal affinity-purified goat antibody (Capra Science, Sweden) against the coating CILP-2 peptide) on non-binding plates (U96 PP 0.5 ml, Natural, Thermo Scientific) for 1 h. The blocked plates were washed with PBS-T four times and the pre-incubated sample was transferred to the freshly washed plates followed by further incubation at room temperature for 2 h. After washing with PBS-T (6 times) TMB substrate (Medicago) was added and the signal allowed developing for 20 min protected from light. The reaction was stopped by the addition of 0.5 M H2SO4 before reading the plates at 450 nm. Samples were analysed in duplicate (patient samples from BL and FU were run on the same plate). The CILP-2 assay standard, a 16 kDa protein (His6tagged aa C206-P246 merged with V551-D611) was produced in E. coli and IMAC/Ni2+ column purified. Standard curve was produced by spiking standard protein to non-detecting CILP-2 serum. The CILP-2 competitive assay had an intra assay variation of 11.1% and the inter assay variations for high control was 20.7% and for low control 22.2%. All analyses were carried out without any prior knowledge of the individual samples.

**Statistical analysis**

Quantitative variables are expressed as means and 95% confidence intervals unless stated otherwise. Data were assessed for normality using the Shapiro-Wilk test. Demographic variables and patient-rated outcome scores were normally distributed, whereas biomarker data were not. Adolescents were stratified by BL growth plate status (open or closed) for biomarker comparisons. Differences in BL and FU biomarker levels between the three groups (BL open adolescents, BL closed adolescents, and adults) were assessed with Kruskal Wallis tests, with pairwise post-hoc analyses when significant adjusted for multiple testing. Differences in biomarker levels between adults with and without prior knee injuries were assessed with Mann Whitney U tests. As there was only one adolescent with prior knee injury, no comparison in biomarkers was made between adolescents with and without prior knee injury. Differences in demographic variables and patient-rated outcomes were assessed with Student’s t-tests. Longitudinal changes in biomarkers were assessed with Wilcoxon Signed Rank tests. Correlations between patient-rated outcomes and longitudinal biomarker changes were assessed with Spearman’s Rank Correlations. An r-value of 0.1 to 0.39 was considered a weak correlation, an r-value of 0.4 to 0.6 was considered a moderate correlation, and an r-value of 0.61 to 1.0 was considered a strong correlation. A one-way ANOVA was used to compare IKDC and SF-36 scores between BL closed adolescents, BL open...
adolescents, and adults. All statistical tests were conducted using SPSS Statistics 18 (IBM SPSS Statistics, USA) with a significance level of 0.05.

Results

Patient-rated outcomes

At BL, adults had a mean IKDC score of 94.3 (range, 75.8 to 100.0) and a mean SF-36 PCS of 53.4 (range, 47.5 to 56.9). Adolescents had a mean IKDC score of 93.9 (range, 70.1 to 100.0) and a mean SF-36 PCS of 55.5 (range, 36.6 to 65.9). There were no significant differences found in IKDC score ($p = 0.885$) or SF-36 PCS ($p = 0.193$) between age groups. Adults with prior knee injuries had significantly worse SF-36 PCS than adults without prior knee injuries (52.4 [50.8, 54.1] vs. 54.9 [53.3, 56.4], $p = 0.033$). The comparison of IKDC and SF-36 scores between BL closed adolescents, BL open adolescents, and adults showed no significant differences between the groups ($P \geq 0.145$).

Growth plate status

At BL, 13 of the 18 adolescents (72%) had open tibial and femoral growth plates, and were classified as BL open adolescents for all analyses, and two boys and three girls had closed growth plates, and were classified as BL closed adolescents for all analyses. At FU, all adolescents, except for one male, had closed growth plates.

Biomarkers

BL and FU biomarker values are shown in Table 2. At both BL and FU, C2C-HUSA was greater in BL open adolescents than in adults ($p < 0.001$). At BL, C2C-HUSA was also greater in BL closed adolescents than in adults ($p = 0.007$) but not at FU ($p = 0.112$). At both BL and FU, CTX-II was greater in BL open adolescents than in adults ($p < 0.001$). CTX-II was also greater in BL closed adolescents than in adults at BL ($p = 0.030$) and FU ($p = 0.034$). Longitudinal changes in biomarkers are shown in Table 3 and Fig. 1. BL open adolescents showed decreases in CPII ($p = 0.028$), C2C-HUSA ($p = 0.012$), and CTX-II ($p = 0.002$). BL closed adolescents showed no changes in biomarker levels from BL to FU ($p \geq 0.080$). Adults exhibited increases in CILP-2 ($p = 0.021$) and C2C-HUSA ($p = 0.033$) from BL to FU. There were no significant differences found in biomarker levels at BL or FU between adults with and without prior knee injuries ($p \leq 0.206$).

Correlations between patient-rated outcomes and longitudinal biomarker changes

Results of correlation analyses are shown in Tables 4 and 5. In adolescents, BL IKDC scores were found to be significantly and strongly correlated with CPII longitudinal changes ($r = -0.662$, $p = 0.037$; Fig. 2). In adults, BL SF-36 PCS were found to be significantly and moderately correlated with COMP longitudinal changes ($r = -0.519$, $p = 0.027$; Fig. 3).

| Table 2 Biomarker Values | BL Open Adolescents | BL Closed Adolescents | Adults | $P$-value |
|--------------------------|---------------------|-----------------------|--------|-----------|
| CILP-2 [ng/ml]           | BL                  | 0.56 (−0.059, 1.2)    | 0.98 (0.60, 1.4) | 1.4 (0.90, 2.0) | 0.13 |
|                         | FU                  | 2.2 (1.4, 3.1)        | 3.0 (1.3, 4.6) | 2.6 (2.0, 3.2) | 0.775 |
| COMP [LU/l]              | BL                  | 15.2 (11.8, 18.5)     | 11.5 (3.7, 19.3) | 12.8 (10.8, 14.8) | 0.406 |
|                         | FU                  | 15.0 (13.1, 16.8)     | 12.1 (6.7, 17.6) | 13.4 (11.8, 15.0) | 0.537 |
| sC2C [ng/ml]             | BL                  | 167.9 (108.6, 227.1)  | 137.5 (18.6, 256.4) | 120.5 (90.3, 150.7) | 0.177 |
|                         | FU                  | 123.3 (105.8, 140.7)  | 113.4 (70.2, 156.6) | 159.6 (120.0, 199.3) | 0.241 |
| CPII [ng/ml]             | BL                  | 310.4 (212.8, 407.9)  | 177.2 (−5.1, 359.5) | 199.3 (139.7, 258.9) | 0.164 |
|                         | FU                  | 176.9 (139.7, 214.1)  | 161.8 (42.5, 281.0) | 262.9 (144.7, 381.0) | 0.862 |
| C2C-HUSA [ng/mmol]       | BL                  | 7.4 (2.3, 12.6)       | 3.6 (0.21, 7.0) | 0.43 (0.33, 0.53) | <0.001 * 0.007 ** |
|                         | FU                  | 3.2 (1.9, 4.5)        | 1.3 (0.53, 2.0) | 0.54 (0.39, 0.69) | <0.001 * 0.112 ** |
| CTX-II [ng/mmol]         | BL                  | 10,675.6 (6038.9, 15,312.3) | 3710.8 (259.7, 7161.9) | 255.4 (177.2, 333.7) | <0.001 * 0.030 ** |
|                         | FU                  | 3312.2 (2255.6, 4368.9) | 1499.8 (1181.6, 1818.1) | 281.1 (203.5, 358.7) | <0.001 * 0.034 ** |

* Statistically significant difference between BL open adolescents and adults
** Statistically significant difference between BL closed adolescents and adults

* BL baseline, FU follow-up, BL Open Adolescents adolescents with open growth plates at BL, BL Closed Adolescents adolescents with closed growth plates at BL. Data provided as mean (95% confidence interval). $P$-values refer to differences between the three groups at BL or FU.
Discussion
The primary aims of this study were to compare biomarkers of cartilage turnover in adolescent and adult volleyball athletes over 2 years. Our main findings were that in adolescents, regardless of growth plate status, there were higher levels of C2C-HUSA and CTX-II than in adults. Adolescents with BL open growth plates showed decreases in CPII, C2C-HUSA, and CTX-II, whereas adults showed increases in C2C-HUSA and CILP-2, and adolescents with closed BL growth plates showed no biomarkers changes from BL to FU. IKDC scores were correlated with CPII changes in adolescents, whereas SF-36 scores were correlated with COMP changes in adults.

Table 3 Biomarker Longitudinal Changes a

|                      | BL Open Adolescents | P-value | BL Closed Adolescents | P-value | Adults | P-value |
|----------------------|---------------------|---------|-----------------------|---------|--------|---------|
| CILP-2 [ng/ml]       | 0.79 (−0.32, 1.9)   | 0.116   | 1.8 (−0.72, 4.4)      | 0.144   | 1.2 (0.23, 2.1) | 0.021* |
| COMP [U/l]           | 1.3 (−14.4, 4.1)    | 0.917   | 0.13 (−8.5, 8.7)      | >0.999  | 0.44 (−14.2, 2.3) | 0.948  |
| sC2C [ng/ml]         | −54.3 (−1314, 22.7) | 0.116   | −36.3 (−142.6, 70.1)  | 0.273   | 43.1 (−14.4, 100.7) | 0.17   |
| CPII [ng/ml]         | −128.8 (−2314, −26.2) | 0.028*  | −57.9 (−253.1, 137.2) | 0.273   | 73.4 (−75.1, 221.8) | 0.586  |
| C2C-HUSA [ng/mmol]   | −7.8 (−178.2, 20)   | 0.012*  | −2.5 (−67, 1.6)       | 0.080   | 0.1079 (−0.0061, 0.22) | 0.033* |
| CTX-II [ng/mmol]     | −11,051.3 (−18920.3, −3182.2) | 0.002* | −2652.8 (−7578.2, 2272.7) | 0.080 | 25.6 (−18.5, 69.9) | 0.26 |

*Statistically significant difference (P < 0.05)

a BL baseline, BL Open Adolescents adolescents with open growth plates at BL, BL Closed Adolescents adolescents with closed growth plates at BL. Data provided as mean (95% confidence interval)

Fig. 1 Percentage longitudinal changes in biomarkers in baseline open adolescents, baseline closed adolescents and adults. Error bars represent 95% confidence intervals. *P < 0.05 for change from baseline to follow-up. a Percentage longitudinal changes in all biomarkers and ratios assessed, with the exception of cartilage intermediate layer protein 2 (CILP-2). b Percentage longitudinal change in cartilage intermediate layer protein 2 (CILP-2)
in adults is likely reflective of cartilage breakdown (Tamm et al. 2014). The increase of C2C-HUSA we found in patients with early articular cartilage degeneration was correlated with more severe knee cartilage lesions, lower Knee Injury and Osteoarthritis Outcome Scores (KOOS), and worse functional abilities of the lower limb (Kane et al. 2006). They concluded that C2C-HUSA may reflect more short-term, immediate cartilage turnover stimulated by high joint loading. This encourages further studies of C2C-HUSA to determine whether it can predict risk of knee OA in this high-risk population.

High levels of the articular cartilage degradative marker CTX-II, the C-telopeptide of type II collagen, have also previously been associated with greater risk (Cibere et al. 2009) and severity (Fang et al. 2001, Jiao et al. 2003). These findings could explain the significantly higher levels of CTX-II in both groups of adolescents than in adult volleyball players in our study at both BL and FU and the decrease in CTX-II from BL to FU in adolescents with and without open growth plates at BL had significantly higher levels of C2C-HUSA at BL than adults, although this did not reach statistical significance at FU for BL closed adolescents. This difference between the age groups is possibly due to the higher volleyball training intensity in the adolescents in comparison to the adults, which may have led to a higher rate of immediate cartilage degradation in the adolescents, and suggests that C2C-HUSA may reflect more short-term, immediate cartilage turnover stimulated by high joint loading. This encourages further studies of C2C-HUSA.

Table 4 Spearman’s Correlations Between Baseline Patient-Rated Outcomes and Longitudinal Biomarker Changes in Adolescents a

| Biomarker | r    | P-value | SF-36 PCS | SF-36 MCS |
|-----------|------|---------|-----------|-----------|
| CILP      | 0.695 | 0.233   | 0.559     | 0.590     |
| COMP      | 0.114 | 0.519   | 0.789     | 0.941     |
| sC2C      | 0.457 | 0.207   | 0.332     | 0.501     |
| CPII      | 0.175 | 0.500   | 0.912     | 0.127     |
| CTX-II    | 0.175 | 0.207   | 0.332     | 0.501     |

*Statistically significant difference (P < 0.05)

* N = 10 for all correlation analyses due to one adolescent male and five adolescent females missing baseline serum samples, and one adolescent male missing a follow-up serum sample.

Table 5 Spearman’s Correlations Between Baseline Patient-Rated Outcomes and Longitudinal Biomarker Changes in Adults a

| Biomarker | r    | P-value | SF-36 PCS | SF-36 MCS |
|-----------|------|---------|-----------|-----------|
| CILP      | 0.457 | 0.207   | 0.332     | 0.501     |
| COMP      | 0.175 | 0.500   | 0.912     | 0.127     |
| sC2C      | 0.193 | 0.130   | 0.130     | 0.130     |
| CPII      | 0.230 | 0.049   | 0.049     | 0.049     |
| CTX-II    | 0.027 | 0.980   | 0.980     | 0.980     |

* N = 18 for all correlation analyses due to one adult female missing a baseline serum sample, except for C2C-HUSA.
suggesting that CTX-II reflects mechanical loading-induced cartilage turnover, making it a promising biomarker to assess pre-OA cartilage changes in an athletic, high-risk population.

CILP-2 is homologous to CILP-1, cartilage intermediate layer protein-1, which is expressed in the intermediate zone of articular cartilage and has been associated with cartilage degenerative diseases (Lorenzo et al. 1998). CILP-2 is more localized to the deeper intermediate zone of articular cartilage at maturity, and its expression has been found to be downregulated in mice with experimentally-induced degenerative OA (Bernardo et al. 2011). One study also found CILP-2 to be decreased in adults with radiographic knee OA.
COMP, cartilage oligomeric matrix protein, is a non-collagenous protein which binds and stabilizes type II collagen fibers and is found in synovium, ligamentous tissue, tendon, meniscus, and particularly articular cartilage (Hoch et al. 2012). In adults, SF-36 PCS scores were moderately correlated with COMP changes. We found that adults with prior knee injuries had significantly worse SF-36 PCS than those without prior knee injuries, although there was no difference in COMP levels found between these two groups. Previous studies have found serum COMP to increase in runners after a marathon (Neidhart et al. 2000, Kim et al. 2009), but another found that increased COMP in college soccer players over a season did not reach the calculated minimum detectable change (Hoch et al. 2012). Kersting et al. found that COMP levels did not significantly change after a 1-h training session, but noted that the standard deviation and range of COMP levels were notably increased post-exercise, indicating that changes may have occurred, albeit in different directions (Kersting et al. 2005). The COMP levels in our adult volleyball players also ranged widely at each point, with ranges of 14.1 U/l and 12.4 U/l at BL and FU, respectively. This may be why we did not find the COMP level to statistically significantly change over time in the adults, although there were enough changes to correlate with SF-36 PCS scores. This suggests that adult volleyball athletes with worse overall physical status, regardless of prior injury status, tended to have increases in COMP over 2 years. Although the causes for this are unclear, larger studies with longer follow-up times are required to assess how COMP reflects patient-rated outcomes and cartilage changes in high-risk populations.

This study had several limitations. A number of subjects were missing serum samples at either BL or FU, which decreased our sample size. Many subjects also had prior knee injuries; however, we aimed to assess how biomarkers of cartilage turnover were affected over time in active volleyball athletes, including those who had recovered from prior knee injuries. We also compared biomarker values and patient-rated outcomes between these subgroups in the adults. Patient-reported outcomes were not collected at FU, so longitudinal changes in this measure could not be assessed.

There were also strengths to this study. Our cohort consisted of two highly uniform age groups with different levels of volleyball participation for comparison. Biomarkers were assessed from both serum and urine samples, which provided a comprehensive assessment of metabolic and pathophysiological cartilage changes. Patient-rated outcomes in both a knee-specific and general health score were used to assess subjective clinical outcomes at BL, which provided a more holistic picture of subjective clinical status. This is also the first study to assess long-term changes in biomarkers of cartilage turnover in adolescent and adult volleyball athletes.

Conclusions
In conclusion, we found that the assessment of different biomarker levels and their changes over time is feasible in adolescent volleyball athletes with both open and closed growth plates, even though they still grow, and adult volleyball athletes. Specifically, adolescent volleyball athletes with both open and closed growth plates had higher levels of the type II collagen degradative biomarkers C2C-HUSA and CTX-II at BL than adult volleyball athletes. Further, we found that CPII, C2C-HUSA, and CTX-II decreased in BL open adolescents, and that C2C-HUSA and CILP-2 increased in adult volleyball athletes over 2 years. These findings suggest that these biomarkers reflect differences in cartilage responses to high-impact joint loading in athletes of different ages and stages of development. The associations between patient-rated outcomes with CPII and COMP changes suggest that these biomarkers may reflect patients’ subjective clinical status. Future studies are required to assess how these biomarkers relate to the risk of future development of OA in athletes.

Abbreviations
ACL: Anterior Cruciate Ligament; BL: Baseline; C2C-HUSA: Cartilage degradation-based biomarkers 45 mer collagenase peptide of type II collagens; CILP-2: Cartilage intermediate layer protein 2; COMP: Cartilage oligomeric matrix protein; CPII: Collagen synthesis marker C-propeptide of type II procollagen; CTX-II: C-telopeptide of type II collagen; FU: 2-year follow-up; IKDC: International Knee Documentation Committee; MCS: Mental Component Score; MEDIC: Multi-Echo Data Image Combination; MRI: Magnetic Resonance
Imaging; OA; Osteoarthritis; PACS; Picture archiving communications system; PCS; Physical Component Score; PD; Proton-density; sC2C; Serum type II collagen cleavage neoepitope; SF-36; Short-Form 36

Acknowledgments
We would like to thank Suzanne Bourbon from IBEX Technologies, Montreal for technical assistance with molecular biomarker analysis. Late Prof. Dick Heinegård (Lund University) and Dr. Jan Hed (AnaMar AB) are greatly acknowledged for their contributions to this work.

Funding
This work was funded by the EndoVerein, the European Community’s Seventh Framework Program-2 (FP7-NMP-2008-Large-2) under grant agreement No. 228929 (NanoDiaRA), the German Research Community (DU 298/20-1) and the German Federal Ministry of Education and Research (BMBF 01EC1408A; Overload-PrevOP; SPO3).

Authors’ contributions
BH contributed to the conception and design of the study, the acquisition, analysis and interpretation of data, drafting the article and the final approval of the version to be submitted. DGN contributed to the conception and design of the study, revising it critically for important intellectual content and the final approval of the version to be submitted. MMA, PAR, BF, ÖP and LP. contributed to the analysis and interpretation of data, drafting the article and the final approval of the version to be submitted. KC and PA. contributed to design and technical assistance of the CILP-2 assay, analysis and interpretation of data, drafting the article and the final approval of the version to be submitted. All authors have read and approved the final submitted manuscript.

Competing interests
The authors have no conflict of interest with the exception of Robin Poole who is a consultant to IBEX Technologies, Montreal, Canada. Anna Pramhed and Cecilia Klint own stock options in AnaMar AB.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the responsible ethics committee (Charité – Universitätsmedizin Berlin, EA2/055/10), and all patients provided written informed consent.

Declarations
The authors have nothing to declare.

Received: 7 December 2016 Accepted: 10 February 2017

Published online: 23 February 2017

References
Ahlen M, Roshani L, Liden M, Struglics A, Rostgard-Christensen L, Kartus J (2015) Inflammatory cytokines and biomarkers of cartilage metabolism 8 years after anterior cruciate ligament reconstruction: results from operated and contralateral knees. Am J Sports Med 43(6):1460–1466
Amnao AO, Pujalte GG (2014) Osteoarthritis in young, active, and athletic individuals. Clin Med Insights Arthritis Musculoskelet Disord 7:27–32
Bernardo BC, Belluccio D, Rowley L, Little CB, Hansen U, Bateman JF (2011) Cartilage intermediate layer protein 2 (CILP-2) is expressed in articular and meniscal cartilage and down-regulated in experimental osteoarthritis. J Biol Chem 286(43):37758–37767
Buckwalter JA, Lane NE (1997) Athletics and osteoarthritis. Am J Sports Med 25(6):873–881
Cibere J, Zhang H, Gamero P, Poole AR, Lobanov T, Saxne T, Kraus VB, Way A, Thome A, Wong H, Singer J, Kopech, Juergens A, Petercy C, Nicolau C, Munik PL, Esaadle JM (2009) Association of biomarkers with pre-radio graphically defined and radio graphically defined knee osteoarthritis in a population-based study. Arthritis Rheum 60(3):1372–1380
Ding C, Gamero P, Cicuttini F, Scott F, Cooley H, Jones G (2005) Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis Cartilage 13(3):198–205
Eckstein F, Boeth H, Diederichs G, Winth W, Hudelmaier M, Cotofana S, Hofmann-Amttenbrink M, Duda G (2014) Longitudinal change in femorotibial cartilage thickness and subchondral bone plate area in male and female adolescent vs. mature athletes. Ann Anat 196:2–3:150–157
Fang C, Johnson D, Leslie MP, Carlson CS, Robbins M, Di Cesare PE (2001) Tissue distribution and measurement of cartilage oligomeric matrix protein in patients with magnetic resonance imaging-detected bone bruises after acute anterior cruciate ligament tears. J Orthop Res 19(4):634–641
Felison DT (2014) Osteoarthritis: priorities for osteoarthritis research: much to be done. Nat Rev Rheumatol 10(8):447–448
Felison DT, Lawrence RC, Dieppe PA, Hirsch R, Heldick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlinden T, Spector TD, Poole AR, Yanovski SZ, Atreshan G, Sharma L, Buckwalter JA, Brandt KD, Fries JF (2000) Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133(8):635–646
Frantz NZ, Friesen KG, Andrews GA, Tokach MD, Yamka RM, Loughlin TL, Nelsen JL, Dritz SS (2010) Use of serum biomarkers to predict the development and severity of osteochondrosis lesions in the distal portion of the femur in pigs. Am J Vet Res 71(8):946–952
Hallett M, Andrich J (1994) Effects of exercise on articular cartilage. Sports Med Arthrosc Rev 2(1):29–37
Hoch JM, Mattacola CG, Bush HM, Medina Mckeen JM, Hewett TE, Latterman C (2012) Longitudinal documentation of serum cartilage oligomeric matrix protein and patient-reported outcomes in collegiate soccer athletes over the course of an athletic season. Am J Sports Med 40(11):2583–2589
Imgang LJ, Anderson AF, Boland AL, Hamer CD, Kuorinka M, Neypert P, Richmond JC, Shelbourne KD (2001) Development and validation of the international knee documentation committee subjective knee form. Am J Sports Med 29(5):600–613
Jiao Q, Wei L, Chen C, Li P, Wang X, Li Y, Guo L, Zhang C, Wei X (2016) Cartilage oligomeric matrix protein and hyaluronic acid are sensitive serum biomarkers for early cartilage lesions in the knee joint. Biomarkers 21(2):146–151
Kersting UG, Stubendorff JJ, Schmidt MC, Bruggemann GP (2005) Changes in knee cartilage volume and serum COMP concentration after running exercise. Osteoarthritis Cartilage 13(10):925–934
Kim HJ, Lee YH, Kim CK (2009) Changes in serum cartilage oligomeric matrix protein (COMP), plasma CPK and plasma hs-CRP in relation to running distance in a marathon (42.195 km) and an ultra-marathon (200 km) race. Eur J Appl Physiol 105(5):765–770
Kujala UM, Kaprio J, Sarna S (1994) Osteoarthritis of weight bearing joints of lower limbs in former elite male athletes. BMJ 308(6923):231–234
Kujala UM, Kettunen J, Paananen H, Aalto T, Bateman JF, Impivaara O, Videnman T, Sarna S (1995) Knee osteoarthritis in former runners, soccer players, weight lifters, and shooters. Arthritis Rheum 38(4):539–546
Kumahashi N, Sword P, Larsson S, Lohmander LS, Frobell R, Stuligros A (2015) Type II collagen C2C epitope in human synovial fluid and serum after knee injury—associations with molecular and structural markers of injury. Osteoarthritis Cartilage 23(9):1506–1512
Lorenzo P, Bayliss MT, Heinegard D (1998) A novel cartilage protein (CILP) present in the mid-zone of human articular cartilage increases with age. J Biol Chem 273(26):23463–23468
Mateer JL, Hoch JM, Mattacola CG, Butterfield TA, Latterman C (2015) Serum Cartilage Oligomeric Matrix Protein Levels in Collegiate Soccer Athletes over the Duration of an Athletic Season: a Pilot Study. Cartilage 6(1):11–11
Mouritzen U, Christgau S, Lehmann H, Tanko LB, Christiansen C (2003) Changes in serum cartilage oligomeric matrix protein and hyaluronic acid after knee injury in normal, overweight and obese female adolescent athletes. Eur J Endocrinol 149(1):77–83
Niemann M, Droege A, Plaas E, Moghadam F, Sigurdsson E, Li X, Lohmander LS, Struglics A (2015) Type II collagen C2C epitope in human subchondral bone: serum and cartilage collagen levels, and associations with molecular and structural markers of injury. Osteoarthritis Cartilage 23(9):1506–1512
Niehoff A, Boeth H, Struglics A, Boeth E, Muller-Ladner U, Muller-Mellin V, Dehning E, Fries JF, Muller-Lung U, Bruggemann GP (2011) Deformational behaviour of knee cartilage and subchondral bone changes in serum cartilage oligomeric matrix protein (COMP) after running and drop landing. Osteoarthritis Cartilage 19(8):1003–1010
O’Kane JW, Hutchinson E, Atley LM, Eyre DR (2006) Sport-related differences in biomarkers of bone resorption and cartilage degradation in endurance athletes. Osteoarthritis Cartilage 14(1):71–76

Patel AA, Donegan D, Albert T (2007) The 36-item short form. J Am Acad Orthop Surg 15(2):126–134

Richmond SA, Fukuchi RK, Ezzat A, Schneider K, Schneider G, Emery CA (2013) Are joint injury, sport activity, physical activity, obesity, or occupational activities predictors for osteoarthritis? a systematic review. J Orthop Sports Phys Ther 43(8):515–8519

Rousseau JC, Delmas PD (2007) Biological markers in osteoarthritis. Nat Clin Pract Rheumatol 3(6):346–356

Saxon L, Finch C, Bass S (1999) Sports participation, sports injuries and osteoarthritis: implications for prevention. Sports Med 28(2):123–135

Soder RB, Simoes JD, Soder JB, Baldisserotto M (2011) MRI of the knee joint in asymptomatic adolescent soccer players: a controlled study. AJR Am J Roentgenol 196(1):W61–65

Struglics A, Larsson S, Kumahashi N, Frobell R, Lohmander LS (2015) Changes in Cytokines and Aggrecan ARGs Neoepitope in Synovial Fluid and Serum and in C-Terminal Crosslinking Telopeptide of Type II Collagen and N-Terminal Crosslinking Telopeptide of Type I Collagen in Urine Over 5 Years After Anterior Cruciate Ligament Rupture: An Exploratory Analysis in the Knee Anterior Cruciate Ligament, Nonsurgical Versus Surgical Treatment Trial. Arthritis Rheumatol 67(7):1816–1825

Tamm A, Kumm J, Tammi A, Linthop M, Kukner A, Saluse T, Rips L, Tein T, Pintsaar A (2014) Cartilage collagen neoepitope C2C and clinical parameters in middle-aged patients with knee problems: Correlations of urinary output of C2C with cartilage lesions, KOOS values and functional abilities of lower limb. Osteoarthritis Cartilage 22:S70–S71